Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Current Assets (2022 - 2025)

Mangoceuticals' Current Assets history spans 4 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 1947.01% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 1947.01% increase, with the full-year FY2025 number at $1.5 million, up 1947.01% from a year prior.
  • Current Assets hit $1.5 million in Q4 2025 for Mangoceuticals, up from $598223.0 in the prior quarter.
  • Over the last five years, Current Assets for MGRX hit a ceiling of $3.8 million in Q1 2023 and a floor of $75595.0 in Q4 2024.
  • Historically, Current Assets has averaged $995866.0 across 4 years, with a median of $598223.0 in 2025.
  • Biggest five-year swings in Current Assets: plummeted 97.65% in 2024 and later soared 1947.01% in 2025.
  • Tracing MGRX's Current Assets over 4 years: stood at $694605.0 in 2022, then grew by 20.27% to $835402.0 in 2023, then tumbled by 90.95% to $75595.0 in 2024, then soared by 1947.01% to $1.5 million in 2025.
  • Business Quant data shows Current Assets for MGRX at $1.5 million in Q4 2025, $598223.0 in Q3 2025, and $117961.0 in Q2 2025.